Bronchiectasis Drugs Market, By Drug Class (Antibiotics, Mucolytics, Bronchodilators, Anti-inflammatory agents), By Route of Administration (Oral, Inhalation, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
The global bronchiectasis drugs market size is estimated to be valued at US$ 334.8 million in 2023 and is expected to reach US$ 660.7 million by 2030, grow at a compound annual growth rate (CAGR) of 10.2 % from 2023 to 2030.
Bronchiectasis is a chronic respiratory condition characterized by the widening of the bronchial tubes, leading to recurrent infections and inflammation. The market for bronchiectasis drugs includes a range of medications such as antibiotics, mucolytics, inhaled corticosteroids, and bronchodilators, which are used to manage symptoms, reduce exacerbations, and improve overall lung function.
With a growing patient population and a greater awareness of bronchiectasis, pharmaceutical companies are investing in research and development to bring new and innovative drugs to the market. These efforts aim to provide patients with more effective and personalized treatment options. Additionally, collaborations between healthcare providers, researchers, and industry players are contributing to advancements in bronchiectasis management, leading to an expansion of the bronchiectasis drugs market.
Bronchiectasis Drugs Market Regional Insights
North America: North America is the largest market for bronchiectasis drugs, accounting for a share of over 47% in 2022. The North American region, particularly the U.S., has a significant share in the bronchiectasis drugs market. This can be attributed to factors such as a high prevalence of bronchiectasis, advanced healthcare infrastructure, and strong research and development activities in the pharmaceutical industry. Additionally, regulatory approvals and reimbursements for bronchiectasis drugs in this region contribute to market growth.
Europe: Europe is the second-largest market for bronchiectasis drugs, accounting for a share of over 30% in 2022. Europe is another key market for bronchiectasis drugs. Countries such as the U.S., Germany, France, and Italy have a substantial patient population and well-established healthcare systems. The region's focus on innovation and access to advanced therapies drives the development and adoption of bronchiectasis drugs.
Asia Pacific: Asia Pacific is the fastest-growing market for bronchiectasis drugs, accounting for a growth rate of over 12.8% in 2022. The Asia Pacific region is witnessing rapid growth in the bronchiectasis drugs market. Increasing awareness of respiratory diseases, improving healthcare infrastructure, and a growing patient population contribute to market expansion. Countries such as China, Japan, and India are key contributors to market growth in this region.
Figure 1. Global Bronchiectasis Drugs Market Share (%), by Region, 2023
Analysts’ Views on Global Bronchiectasis Drugs Market:
Bronchiectasis is a chronic condition characterized by the permanent enlargement of parts of the airways of the lung. Symptoms typically include a chronic cough with mucus production. The global bronchiectasis drugs market is expected to witness significant growth in the coming years. This growth is primarily driven by the increasing prevalence of bronchiectasis worldwide, advancements in drug development, and rising awareness about the disease.
Bronchiectasis Drugs Market Drivers:
Increasing Prevalence of Bronchiectasis: The rising prevalence of bronchiectasis worldwide is a significant driver for the market. Factors such as aging populations, improved diagnostics, and increased awareness of the condition contribute to the growing number of diagnosed cases. As the patient population expands, there is a higher demand for effective drugs to manage bronchiectasis symptoms and improve patients' quality of life. For instance, according to the data published by the National Center for Biotechnology Information (NCBI) on July 1, 2022, the prevalence of bronchiectasis has been found to range from 67 to 566.1 per 100,000 inhabitants in Europe and North America.
Increasing Awareness of the Disease: Increasing awareness of the disease globally will aid in market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information (NCBI) on July 1, 2022, global lung health organizations from the USA, Europe, Australia, and Asia joined together to declare July 1, 2022 as the first ‘World Bronchiectasis Day’ to raise awareness about bronchiectasis. The motive of the day is to emphasize the increased prevalence of bronchiectasis globally and to increase awareness and promote effective diagnosis and management of this rather neglected disease.
Bronchiectasis Drugs Market Opportunities:
Unmet Medical Needs: Despite advancements in treatment options, there are still unmet medical needs in the bronchiectasis drugs market. Opportunities exist for the development of novel drugs that can address specific challenges in managing the condition, such as reducing exacerbations, improving lung function, and enhancing quality of life for patients. Targeting these unmet needs can lead to the introduction of innovative therapies and drive market growth.
Emerging Markets: There are growing opportunities in emerging markets, particularly in regions such as Asia Pacific, Latin America, and the Middle East. These markets have a rising prevalence of bronchiectasis and an increasing demand for effective treatment options. Expanding market reach to these emerging markets, adapting to local healthcare systems, and addressing specific regional needs can lead to significant market growth opportunities. For instance, according to the data published by the Korean Journal of Internal Medicine on June 16, 2021, the prevalence of idiopathic bronchiectasis was higher in Asia (59.2%) than in Europe (41.1%).
Bronchiectasis Drugs Market Report Coverage
Report Coverage
Details
Base Year:
2022
Market Size in 2023:
US$ 334.8 Mn
Historical Data for:
2018 to 2021
Forecast Period:
2023 - 2030
Forecast Period 2023 to 2030 CAGR:
10.2%
2030 Value Projection:
US$ 660.7 Mn
Geographies covered:
North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East & Africa: GCC Countries, Israel, South Africa, North Africa, and Central Africa and Rest of Middle East
Segments covered:
By Drug Class: Antibiotics, Mucolytics, Bronchodilators, Anti-inflammatory agents
By Route of Administration: Oral, Inhalation, Intravenous
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Focus on Innovative Therapies: There is growing emphasis on launching innovative therapies for the treatment of bronchiectasis. For instance, on March 23, 2023, Insmed Incorporated, a global biopharmaceutical company, announced that adult patient enrollment is complete in its pivotal ASPEN study of brensocatib.
Expansion of Biologics and Targeted Therapies: Biologics and targeted therapies are gaining attention in the bronchiectasis drugs market. These treatments are designed to selectively target specific molecules or pathways involved in the disease process. Biologics such as monoclonal antibodies and novel small molecules offer the potential for more precise and effective interventions. Ongoing research is exploring the use of targeted therapies to reduce inflammation, control infection, and improve lung function in bronchiectasis patients.
Bronchiectasis Drugs Market Restraints:
Limited Awareness and Underdiagnosis: Bronchiectasis is often underdiagnosed or misdiagnosed, leading to delayed or inadequate treatment. Limited awareness among healthcare professionals and the general population about the condition can hinder early detection and appropriate management. The lack of recognition and understanding of bronchiectasis may result in a smaller market size than the actual patient population, impacting overall market growth. For instance, according to the data published by Springer Nature in 2021, underdiagnosis of obstructive lung disease (OLD) such as bronchiectasis is very common among French adults, even in patients with respiratory symptoms.
Increasing awareness and increasing diagnosis of bronchiectasis will aid in the market growth over the forecast period.
High Development Costs and Regulatory Hurdles: Developing and bringing new bronchiectasis drugs to market can be costly and time-consuming. The rigorous clinical trial process, regulatory requirements, and market access challenges can create barriers for pharmaceutical companies. The high development costs associated with conducting clinical trials and obtaining regulatory approvals can deter investment in research and development, limiting the availability of innovative therapies.
Recent Developments
Key Developments
On July 18, 2023, Zambon, a multinational pharmaceutical company, announced the final results from the Phase 3 PROMIS-I and PROMIS-II studies, which were presented today at the 2023 6th World Bronchiectasis Conference in New York, NY.
On November 23, 2020, RedHill Biopharma, a pharmaceutical company, launched a Phase 3 clinical trial to evaluate the safety and effectiveness of its investigational oral therapy, RHB-204, in adults with bronchiectasis.
Acquisition and partnerships
In December 2022, LifeArc, a British life science medical research charity, partnered with the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) to improve healthcare for thousands of people across Europe living with bronchiectasis. The three-year partnership, part of LifeArc’s US$100m Chronic Respiratory Infection Translational Challenge, will see LifeArc join more than a dozen organizations in a pan-European effort to deepen understanding of bronchiectasis and deliver new diagnostics and treatments for patients faster.
Figure 2. Global Bronchiectasis Drugs Market Share (%), by Distribution Channel, 2023
Definition: Bronchiectasis drugs refer to medications and therapies specifically designed to treat and manage the symptoms of bronchiectasis, a chronic lung condition characterized by the widening and scarring of the airways. These drugs aim to address the underlying causes of bronchiectasis, such as infection, inflammation, and excessive mucus production.
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
The global Bronchiectasis Drugs Market size was valued at USD 334.8 million in 2023 and is expected to reach USD 660.7 million in 2030.
Limited awareness and underdiagnoses, lack of specific treatment guidelines is expected to hinder the market growth over the forecast period.
Increasing prevalence of bronchiectasis, increasing awareness of the disease are expected to propel the market growth over the forecast period.
The leading component segments in the bronchiectasis drugs market include drug class, due to launch of novel products by the market players.
Major players operating in the Bronchiectasis Drugs market include Bayer AG, GlaxoSmithKline, Boehringer Ingelheim, Novartis, AstraZeneca, Sunovion Pharmaceuticals, and Chiesi Farmaceutici.
North America, particularly the U.S., is expected to lead the bronchiectasis drugs market, followed by Europe and the Asia Pacific.
The CAGR (compound annual growth rate) of the bronchiectasis drugs market is expected to be around 10.2% from 2023 to 2030.
U.S.: 
U.K. : 
India : 
